EP2173773A4 - Bifunktionale fusionsproteine aus dem alpha-melanocyt stimulierenden hormon (alpha-msh) und dem atrialen natriuretischen protein (anp) und ihre verwendung bei hypertonie und akuten nierenschädigungen - Google Patents

Bifunktionale fusionsproteine aus dem alpha-melanocyt stimulierenden hormon (alpha-msh) und dem atrialen natriuretischen protein (anp) und ihre verwendung bei hypertonie und akuten nierenschädigungen

Info

Publication number
EP2173773A4
EP2173773A4 EP08783182A EP08783182A EP2173773A4 EP 2173773 A4 EP2173773 A4 EP 2173773A4 EP 08783182 A EP08783182 A EP 08783182A EP 08783182 A EP08783182 A EP 08783182A EP 2173773 A4 EP2173773 A4 EP 2173773A4
Authority
EP
European Patent Office
Prior art keywords
alpha
anp
msh
hypertension
fusion proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08783182A
Other languages
English (en)
French (fr)
Other versions
EP2173773A1 (de
Inventor
Krishna Peri
Abdelkrim Habi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of EP2173773A1 publication Critical patent/EP2173773A1/de
Publication of EP2173773A4 publication Critical patent/EP2173773A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP08783182A 2007-07-06 2008-07-04 Bifunktionale fusionsproteine aus dem alpha-melanocyt stimulierenden hormon (alpha-msh) und dem atrialen natriuretischen protein (anp) und ihre verwendung bei hypertonie und akuten nierenschädigungen Withdrawn EP2173773A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94829207P 2007-07-06 2007-07-06
PCT/CA2008/001250 WO2009006732A1 (en) 2007-07-06 2008-07-04 Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury

Publications (2)

Publication Number Publication Date
EP2173773A1 EP2173773A1 (de) 2010-04-14
EP2173773A4 true EP2173773A4 (de) 2010-07-07

Family

ID=40221938

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08783182A Withdrawn EP2173773A4 (de) 2007-07-06 2008-07-04 Bifunktionale fusionsproteine aus dem alpha-melanocyt stimulierenden hormon (alpha-msh) und dem atrialen natriuretischen protein (anp) und ihre verwendung bei hypertonie und akuten nierenschädigungen

Country Status (13)

Country Link
US (1) US8822413B2 (de)
EP (1) EP2173773A4 (de)
JP (1) JP2010532323A (de)
KR (1) KR20100029195A (de)
CN (1) CN102066421A (de)
AP (1) AP2009005091A0 (de)
AU (1) AU2008274845A1 (de)
BR (1) BRPI0812947A2 (de)
CA (1) CA2691898A1 (de)
IL (1) IL202610A0 (de)
MX (1) MX2009013372A (de)
RU (1) RU2010103995A (de)
WO (1) WO2009006732A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US20150327525A1 (en) * 2014-05-13 2015-11-19 Charles J. Noack, JR. Valley Hook
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
EP3250227A2 (de) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung eines patienten mit mangel an alkalischer phosphatase
MX2018002121A (es) 2015-08-17 2018-06-18 Alexion Pharma Inc Elaboracion de fosfatasas alcalinas.
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP3385285B1 (de) * 2015-12-18 2020-11-11 Lanzhou University Fusionsprotein für alpha-melanocyt-stimulierendes hormon sowie herstellungsverfahren und verwendung davon
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (de) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie (hpp) bei erwachsenen und jugendlichen
CN107828819B (zh) * 2017-10-30 2020-11-03 武汉生物工程学院 一种利用ANP或IgANP基因构建重组腺病毒的方法及重组腺病毒和应用
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CN112062857A (zh) * 2019-06-10 2020-12-11 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
WO2020250159A1 (en) 2019-06-12 2020-12-17 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
WO2022159382A1 (en) * 2021-01-19 2022-07-28 The Trustees Of Columbia University In The City Of New York Reactivation of mtor in acute kidney injury (aki)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000561A1 (en) * 1988-07-07 1990-01-25 Novo Nordisk A/S Novel peptides
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
AU2005211776B2 (en) 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718665B1 (de) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
MX2007006830A (es) 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
EP2330124B1 (de) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren Eigenschaften
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000561A1 (en) * 1988-07-07 1990-01-25 Novo Nordisk A/S Novel peptides
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAUMANIS VIESTURS ET AL: "Synthesis of recombinant atrial natriuretic peptide (rANP) using hybrid fusion protein-phage fr coat/ANP (CP/ANP)", PEPTIDES (TARRYTOWN), vol. 18, no. 8, 1997, pages 1229 - 1235, XP009133727, ISSN: 0196-9781 *
See also references of WO2009006732A1 *

Also Published As

Publication number Publication date
WO2009006732A9 (en) 2009-03-05
JP2010532323A (ja) 2010-10-07
IL202610A0 (en) 2011-08-01
EP2173773A1 (de) 2010-04-14
MX2009013372A (es) 2010-02-22
US8822413B2 (en) 2014-09-02
US20090011997A1 (en) 2009-01-08
KR20100029195A (ko) 2010-03-16
AU2008274845A1 (en) 2009-01-15
WO2009006732A1 (en) 2009-01-15
RU2010103995A (ru) 2011-08-20
AP2009005091A0 (en) 2009-12-31
CA2691898A1 (en) 2009-01-15
BRPI0812947A2 (pt) 2014-12-23
CN102066421A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
IL202610A0 (en) Bifunctional fusion proteins of the alpha - melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury
IL180364A0 (en) Antibodies directed against amyloid-beta peptide and methods using same
IL248025A0 (en) Antibodies which are antagonists against a peptide relating to the calcitonin gene and methods of using them
AP2007004217A0 (en) Antibodies directed against amyloid-beta peptide and methods using same
EP2102355A4 (de) Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
ZA200707413B (en) Cat allergen fusion proteins and uses thereof
AP2007004034A0 (en) Polypeptides sthat bind br3 and uses thereof
IL208598A0 (en) Human serum albumin linkers and conjugates thereof
IL183450A0 (en) Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
LT2650020T (lt) Trimerinio ox40-immunoglobulino sulietas baltymas ir naudojimo būdai
ZA200804551B (en) Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
ZA200804095B (en) Nucleic acids and proteins associated with galactomannan synthesis in coffee
EP1773385A4 (de) HAUTIMMUNISIERUNG MIT LT-Sta-FUSIONSPROTEINEN
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
GB0714905D0 (en) DNA priming and boosting with fusion peptide
EP1751279A4 (de) An der herstellung von cryptophycin beteiligte nukleinsäuren und polypeptide
PT1833847E (pt) Polipéptidos de fusão que contêm igf-1 e utilizações terapêuticas desses polipéptidos
SI2241575T1 (sl) IGF-1 fuzijski polipeptidi in njihove terapevtske uporabe
HK1082770A1 (en) Supter-antigen fusion proteins and the use thereof
SI1868642T1 (sl) Mačji alergen-fuzijski proteini in njihove uporabe
GB0418156D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
GB0707771D0 (en) Biomarker detection using in vitro synthetized peptides, polypeptides and proteins
AU2004906729A0 (en) Delivery of proteins and peptides
EP2392585A3 (de) Gerüstproteine für rekombinante Peptidaptamere
GB0424871D0 (en) Antibodies and their use in therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100604

RAX Requested extension states of the european patent have changed

Extension state: AL

Payment date: 20091222

Extension state: RS

Payment date: 20091222

Extension state: BA

Payment date: 20091222

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1143171

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1143171

Country of ref document: HK